Cormorant Asset Management LP 13D and 13G filings for Aerovate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 3:08 pm Sale |
2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Cormorant Asset Management LP | 1,211,696 4.380% |
-745,436 (-38.09%) |
Filing |
| 2023-02-14 3:10 pm Purchase |
2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Cormorant Asset Management LP | 1,957,132 7.950% |
126,441 (+6.91%) |
Filing |
| 2022-02-14 3:10 pm Sale |
2021-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE |
Cormorant Asset Management LP | 1,830,691 7.500% |
-200,000 (-9.85%) |
Filing |
| 2021-07-12 4:19 pm Purchase |
2021-07-02 | 13G | Aerovate Therapeutics, Inc. AVTE |
Cormorant Asset Management LP | 2,030,691 8.320% |
2,030,691 (New Position) |
Filing |